From hope to adoption: an industry perspective on the maturation of new approach methodologies
Leandro Royer, Klaus A. Rytved, Lilou Babinet, Mario Beilmann, Harrie Boonen, Nicolas Couvreur, Katja Damme, Ann De Smedt, Ann Doherty, Stefan Kustermann, Ludmilla Mazelin-Winum, Tomas Mow, Teija Oinonen, Thomas Steger-Hartmann, Karen Tilmant, Axel Vicart, Silke Weber, Jon Lyon, Philip Hewitt, Jean-Pierre Valentin Nature Reviews Drug Discovery
· Springer Nature
· 2026-11-13
· DOI: 10.1038/s41573-026-01583-4
Abstract
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/s41573-026-01583-4 From hope to adoption: an industry perspective on the maturation of new approach methodologies
Leandro Royer, Klaus A. Rytved, Lilou Babinet, Mario Beilmann, Harrie Boonen, Nicolas Couvreur et al. From hope to adoption: an industry perspective on the maturation of new approach methodologies. // Nature Reviews Drug Discovery. – 2026. – DOI: 10.1038/s41573-026-01583-4. – URL: https://www.nature.com/articles/s41573-026-01583-4
Leandro Royer, Klaus A. Rytved, Lilou Babinet, Mario Beilmann, Harrie Boonen, Nicolas Couvreur, Katja Damme, Ann De Smedt, Ann Doherty, Stefan Kustermann, Ludmilla Mazelin-Winum, Tomas Mow, Teija Oinonen, Thomas Steger-Hartmann, Karen Tilmant, Axel Vicart, Silke Weber, Jon Lyon, Philip Hewitt, & Jean-Pierre Valentin (2026). From hope to adoption: an industry perspective on the maturation of new approach methodologies. Nature Reviews Drug Discovery. https://doi.org/10.1038/s41573-026-01583-4
Leandro Royer, et al. “From hope to adoption: an industry perspective on the maturation of new approach methodologies.” Nature Reviews Drug Discovery, 2026. doi:10.1038/s41573-026-01583-4.
@article{Royer2026,
title = {From hope to adoption: an industry perspective on the maturation of new approach methodologies},
author = {Royer, Leandro and Rytved, Klaus A. and Babinet, Lilou and Beilmann, Mario and Boonen, Harrie and Couvreur, Nicolas and Damme, Katja and Smedt, Ann De and Doherty, Ann and Kustermann, Stefan and Mazelin-Winum, Ludmilla and Mow, Tomas and Oinonen, Teija and Steger-Hartmann, Thomas and Tilmant, Karen and Vicart, Axel and Weber, Silke and Lyon, Jon and Hewitt, Philip and Valentin, Jean-Pierre},
journal = {Nature Reviews Drug Discovery},
year = {2026},
doi = {10.1038/s41573-026-01583-4},
url = {https://www.nature.com/articles/s41573-026-01583-4}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...